Difference between revisions of "Classification of urothelial carcinoma by immunohistochemistry"
Jump to navigation
Jump to search
| Line 12: | Line 12: | ||
{{familytree | C01 | | | | C02 | | | | | | | | | | | |C01='''Genomically unstable'''<br>'''p16 +ve'''|C02='''Urothelial-like'''<br>'''p16 -ve'''}} | {{familytree | C01 | | | | C02 | | | | | | | | | | | |C01='''Genomically unstable'''<br>'''p16 +ve'''|C02='''Urothelial-like'''<br>'''p16 -ve'''}} | ||
{{familytree/end}} | {{familytree/end}} | ||
Note: | |||
*Twenty percent of the tumour cells is considered the cut-off for ''positive'' and ''negative''.<ref name=pmid34103388/> | |||
==Sign out== | ==Sign out== | ||
Revision as of 17:30, 26 October 2021
A classification of urothelial carcinoma by immunohistochemistry can be done with three immunostains.[1]
General
- A large meta-analysis showed two markers (CK5/6, GATA3) can subclassify ~90% of urothelial carcinoma into prognostic groups.[2]
A simple classification of urothelial carcinoma by immunohistochemistry
| Urothelial carcinoma | |||||||||||||||||||||||||||||||||||||||||
| Luminal type GATA3 +ve (CK5/6 -ve) | Basal type CK5/6 +ve (GATA3 -ve) | ||||||||||||||||||||||||||||||||||||||||
| Genomically unstable p16 +ve | Urothelial-like p16 -ve | ||||||||||||||||||||||||||||||||||||||||
Note:
- Twenty percent of the tumour cells is considered the cut-off for positive and negative.[1]
Sign out
The immunoprofile (GATA3 POSITIVE, p16 POSITIVE, CK5/6 negative,) is in keeping with UROTHELIAL CARCINOMA, LUMINAL TYPE, GENOMICALLY UNSTABLE.
The immunoprofile (GATA3 POSITIVE, p16 negative, CK5/6 negative) is in keeping with UROTHELIAL CARCINOMA, LUMINAL TYPE, UROTHELIAL-LIKE.
The immunoprofile (CK5/6 POSITIVE, GATA3 negative) is in keeping with UROTHELIAL CARCINOMA, BASAL TYPE.
See also
References
- ↑ 1.0 1.1 Olkhov-Mitsel E, Hodgson A, Liu SK, Vesprini D, Xu B, Downes MR (June 2021). "Three-antibody classifier for muscle invasive urothelial carcinoma and its correlation with p53 expression". J Clin Pathol. doi:10.1136/jclinpath-2021-207573. PMID 34103388.
- ↑ Dadhania V, Zhang M, Zhang L, Bondaruk J, Majewski T, Siefker-Radtke A, Guo CC, Dinney C, Cogdell DE, Zhang S, Lee S, Lee JG, Weinstein JN, Baggerly K, McConkey D, Czerniak B (October 2016). "Meta-Analysis of the Luminal and Basal Subtypes of Bladder Cancer and the Identification of Signature Immunohistochemical Markers for Clinical Use". EBioMedicine 12: 105–117. doi:10.1016/j.ebiom.2016.08.036. PMC 5078592. PMID 27612592. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5078592/.